Prelude Therapeutics Inc (PRLD) stock
PRLDNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 8/3055% above fair value
$3.32−0.09 (-2.64%)
Close on Nov 17, 2026Market cap $264.95MP/E –Yield –
Prelude Therapeutics revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Prelude Therapeutics's revenue for the twelve months ending Jun 30, 2026 was $22.42M, up 220.3% year over year. For fiscal 2025 it was $12.14M, up 73.4% from the year before.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $12.14M | +73.4% |
| FY2024 | Dec 31, 2024 | $7.00M | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $5.70M | – |
| Q1 FY2026 | Mar 31, 2026 | $4.58M | – |
| Q4 FY2025 | Dec 31, 2025 | $5.64M | +41.0% |
| Q3 FY2025 | Sep 30, 2025 | $6.50M | +116.7% |
| Q2 FY2025 | Jun 30, 2025 | $0 | – |
| Q1 FY2025 | Mar 31, 2025 | $0 | – |
| Q4 FY2024 | Dec 31, 2024 | $4.00M | – |
| Q3 FY2024 | Sep 30, 2024 | $3.00M | – |
See a number that looks wrong?